Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 39

Publication Record

Connections

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB
(2020) Eur J Cancer 135: 211-220
MeSH Terms: Aged, Antineoplastic Agents, Immunological, B7-H1 Antigen, Body Composition, Female, Functional Status, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Neoplasms, Nutritional Status, Programmed Cell Death 1 Receptor, Progression-Free Survival, Quality of Life, Retrospective Studies, Survivors, Time Factors
Added September 29, 2020
0 Communities
1 Members
0 Resources
18 MeSH Terms
Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.
Davis RJ, Lina I, Ding D, Engle EL, Taube J, Gelbard A, Hillel AT
(2021) Laryngoscope 131: 967-974
MeSH Terms: B7-H1 Antigen, Biopsy, Case-Control Studies, Cells, Cultured, Cricoid Cartilage, Female, Fibroblasts, Fibrosis, Humans, Immunohistochemistry, Laryngostenosis, Male, Middle Aged, Primary Cell Culture, Programmed Cell Death 1 Receptor, Trachea, Tracheal Stenosis, Tracheostomy
Added July 30, 2020
0 Communities
1 Members
0 Resources
18 MeSH Terms
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ
(2020) Br J Clin Pharmacol 86: 1778-1789
MeSH Terms: Drug-Related Side Effects and Adverse Reactions, Humans, Immune Checkpoint Inhibitors, Incidence, Melanoma, Neoplasms, Programmed Cell Death 1 Receptor
Added September 29, 2020
0 Communities
1 Members
0 Resources
7 MeSH Terms
COVID-19 and immune checkpoint inhibitors: initial considerations.
Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL
(2020) J Immunother Cancer 8:
MeSH Terms: Antineoplastic Agents, Immunological, COVID-19, Coronavirus Infections, Humans, Molecular Targeted Therapy, Neoplasms, Pandemics, Pneumonia, Viral, Programmed Cell Death 1 Receptor
Added May 29, 2020
0 Communities
2 Members
0 Resources
9 MeSH Terms
Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.
Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem JE, Johnson DB
(2020) Cancer Immunol Res 8: 851-855
MeSH Terms: Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, CTLA-4 Antigen, Female, Hospitalization, Humans, Immunologic Factors, Immunotherapy, Length of Stay, Male, Melanoma, Middle Aged, Programmed Cell Death 1 Receptor, Risk Factors, Young Adult
Added May 29, 2020
0 Communities
1 Members
0 Resources
19 MeSH Terms
Solid organ transplant rejection associated with immune-checkpoint inhibitors.
Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, Hertig A, Salem JE
(2020) Ann Oncol 31: 543-544
MeSH Terms: Humans, Immune Checkpoint Inhibitors, Organ Transplantation, Programmed Cell Death 1 Receptor
Added May 29, 2020
0 Communities
1 Members
0 Resources
4 MeSH Terms
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE
(2019) Eur J Cancer 123: 112-115
MeSH Terms: Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, CTLA-4 Antigen, Chemical and Drug Induced Liver Injury, Child, Databases, Factual, Female, Hepatitis, Autoimmune, Humans, Ipilimumab, Male, Massive Hepatic Necrosis, Middle Aged, Neoplasms, Nivolumab, Programmed Cell Death 1 Receptor, World Health Organization, Young Adult
Added November 12, 2019
0 Communities
1 Members
0 Resources
23 MeSH Terms
A case report of clonal EBV-like memory CD4 T cell activation in fatal checkpoint inhibitor-induced encephalitis.
Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM
(2019) Nat Med 25: 1243-1250
MeSH Terms: Adolescent, Adult, Aged, Aged, 80 and over, CD4-Positive T-Lymphocytes, Encephalitis, Female, Herpesvirus 4, Human, Humans, Immunologic Memory, Lymphocyte Activation, Male, Middle Aged, Programmed Cell Death 1 Receptor, Young Adult
Added November 12, 2019
0 Communities
1 Members
0 Resources
MeSH Terms
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M
(2019) N Engl J Med 380: 2377-2379
MeSH Terms: Abatacept, Aged, Antineoplastic Agents, Immunological, Female, Humans, Immunosuppressive Agents, Lung Neoplasms, Myocarditis, Myositis, Nivolumab, Programmed Cell Death 1 Receptor
Added November 12, 2019
0 Communities
1 Members
0 Resources
MeSH Terms
Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE
(2019) Eur J Cancer 113: 10-13
MeSH Terms: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, CTLA-4 Antigen, Databases, Factual, Female, Humans, Hypophysitis, Ipilimumab, Male, Middle Aged, Nivolumab, Pharmacovigilance, Programmed Cell Death 1 Receptor, World Health Organization, Young Adult
Added November 12, 2019
0 Communities
1 Members
0 Resources
20 MeSH Terms